Zobrazeno 1 - 10
of 729
pro vyhledávání: ''
Autor:
Samriddhi Buxy, Florian Fischer, Oliver Senn, Rainer Zbinden, Ulrike Held, Franz R. Eberli, Matthias R. Meyer, David J. Kurz
Publikováno v:
The American Journal of Cardiology. 139:15-21
The glycoprotein IIb/IIIa inhibitor eptifibatide, administered as bolus followed by infusion, is an adjunctive antithrombotic treatment during primary percutaneous coronary intervention (PCI) in selected patients with ST-segment elevation myocardial
Publikováno v:
The American Journal of Cardiology. 125:303-308
Serum albumin (SA) level is a powerful cardiovascular prognostic marker, suggested to be involved in regulation of platelet function. High on-aspirin platelet reactivity (HAPR) is associated with increased risk for deleterious cardiovascular events.
Autor:
Jeffrey L. Anderson, Stacey Knight, T. Jared Bunch, Heidi T May, Kirk U. Knowlton, Scott C. Woller, Scott M. Stevens, Tami L Bair, Benjamin A. Steinberg, Scott Rizzi, Joseph B. Muhlestein
Publikováno v:
The American journal of cardiology. 153
Both time in therapeutic range (TTR) for anticoagulation and depression are associated with dementia risk. The purposes of this study were to examine the impact of depression on TTR and to describe the partitioned contribution of depression and TTR o
Autor:
Yusuke Watanabe, Ken Kozuma, Taiga Katayama, Hirofumi Hioki, Shinji Takahashi, Kazuo Kawasugi, Naoyuki Yokoyama
Publikováno v:
The American journal of cardiology. 147
Thromboembolic events remain clinically unresolved after transcatheter aortic valve implantation (TAVI). The use of direct oral anticoagulant (DOAC) to reduce thrombosis associated with TAVI remains controversial. This study aimed at investigating th
Autor:
Yuli Guzman-Prado
Publikováno v:
The American Journal of Cardiology
Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcome
Autor:
Jennifer G. Robinson, Michael J. Louie, Daniel Gaudet, Gerald F. Watts, Frederick J. Raal, Pascal Minini, Jay M. Edelberg, William J. Sasiela
Publikováno v:
The American Journal of Cardiology. 119:40-46
Elevated lipoprotein(a) [Lp(a)] is independently associated with increased cardiovascular risk. However, treatment options for elevated Lp(a) are limited. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, reduced low
Autor:
Alan H.B. Wu, Jasmine Villanueva, Shanmugavel Madasamy, Edward P. Amento, Umadevi Shivasubramani, Marty Bigos
Publikováno v:
The American Journal of Cardiology. 118:1187-1193
Statin drugs are leading medication prescribed for treatment of dyslipidemic patients aimed at preventing both primary and secondary incidences of atherosclerosis-related cardiovascular events. Statin drugs competitively inhibit HMG-CoA reductase enz
Autor:
Kerstin Daemen, Dietmar Boethig, Christine S. Falk, Jana Keil, Anneke Neumann, Christoph Bara, Bianca Przybylek, Axel Haverich, Bianca Borchert-Moerlins
Publikováno v:
The American journal of cardiology. 123(7)
To date, there are no established noninvasive biomarkers available for prediction of cardiac allograft vasculopathy (CAV) after orthotopic heart transplantation (OHT). Inflammatory processes are supposed to play a central role in the pathogenesis of
Autor:
Paul M. Ridker, Nancy R. Cook, Lynda M. Rose, David E. Cohen, Nina P. Paynter, Paulo H Harada
Publikováno v:
The American Journal of Cardiology. 118:49-55
The relation between hepatic serum markers within the normal range and cardiovascular risk is uncertain. We sought to address this issue within a prospective randomized trial of statin therapy. Men and women (n = 17,515) free of cardiovascular diseas
Autor:
Naima Covassin, Amir Lerman, Lukas Ruzek, Tomas Kara, Paul A. Friedman, Celeste Koestler, Filip Soucek, Prachi Singh, Francisco Lopez-Jimenez, Mahmoud Suleiman, Virend K. Somers
Publikováno v:
The American Journal of Cardiology. 116:1443-1446
Epicardial adipose tissue (EAT) has been recognized as a sensitive marker of cardiometabolic risk. Recent evidence suggests efficacy of long-term statin therapy in reducing EAT in patients with coronary artery disease. Whether short-term statin thera